These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31626182)

  • 1. [The pegylated form of interferon beta in the treatment of multiple sclerosis].
    Melnikov MV; Kasatkin DS; Volkov AI; Boyko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(8):136-141. PubMed ID: 31626182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
    Hernandez L; Guo S; Kinter E; Fay M
    J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature.
    Mahurkar S; Suppiah V; O'Doherty C
    Autoimmun Rev; 2014 Feb; 13(2):178-86. PubMed ID: 24189284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatigue Improvement after Switching Multiple Sclerosis Treatment from Interferon-β to Glatiramer Acetate in Clinical Practice.
    Meca-Lallana J; Hernández L; Caminero AB; Girón JM; Cano-Orgaz A; Carcelén-Gadea M; Muñoz D; Durán-Ferreras E; Martín-Hernández J; Sánchez-de la Rosa R;
    Eur Neurol; 2016; 76(1-2):40-7. PubMed ID: 27376845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis.
    Tolley K; Hutchinson M; You X; Wang P; Sperling B; Taneja A; Siddiqui MK; Kinter E
    PLoS One; 2015; 10(6):e0127960. PubMed ID: 26039748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis.
    Duddy M; Palace J
    Pract Neurol; 2016 Feb; 16(1):4-6. PubMed ID: 26430247
    [No Abstract]   [Full Text] [Related]  

  • 8. Disease modifying therapies in multiple sclerosis: could a baseline thyroid check-up drive the therapeutic choice between interferon-β and glatiramer acetate?
    Rotondi M; Bergamaschi R; Chiovato L
    Mult Scler; 2014 Dec; 20(14):1918-9. PubMed ID: 24812044
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current perspectives on interferon Beta-1b for the treatment of multiple sclerosis.
    Marziniak M; Meuth S
    Adv Ther; 2014 Sep; 31(9):915-31. PubMed ID: 25182864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Life to an Old Treatment: Pegylated Interferon Beta 1a in the Management of Multiple Sclerosis.
    Ortiz MA; Espino-Paisan L; Nunez C; Alvarez-Lafuente R; Urcelay E
    Curr Med Chem; 2018; 25(27):3272-3283. PubMed ID: 29484976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.
    Melendez-Torres GJ; Auguste P; Armoiry X; Maheswaran H; Court R; Madan J; Kan A; Lin S; Counsell C; Patterson J; Rodrigues J; Ciccarelli O; Fraser H; Clarke A
    Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of multiple sclerosis: personalized therapy with immunomodulatory drugs.
    Tsareva E; Kulakova O; Boyko A; Favorova O
    Pharmacogenet Genomics; 2016 Mar; 26(3):103-15. PubMed ID: 26678572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The technology of treatment of multiple sclerosis with long-term immunomodulating drugs (disease modifying drugs--DMD)--beta-interferons and glatiramer-acetate].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor)
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):86-92. PubMed ID: 21916162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple sclerosis: expression of CD1a and production of IL-12p70 and IFN-gamma by blood mononuclear cells in patients on combination therapy with IFN-beta and glatiramer acetate compared to monotherapy with IFN-beta.
    Hussien Y; Sanna A; Söderström M; Link H; Huang YM
    Mult Scler; 2004 Feb; 10(1):16-25. PubMed ID: 14760948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of immunomodulatory therapy with interferon-β or glatiramer acetate on multiple sclerosis-associated uveitis.
    Velazquez-Villoria D; Macia-Badia C; Segura-García A; Pastor Idoate S; Arcos-Algaba G; Velez-Escola L; García-Arumí J
    Arch Soc Esp Oftalmol; 2017 Jun; 92(6):273-279. PubMed ID: 28188020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse.
    Cohen BA; Coyle PK; Leist T; Oleen-Burkey MA; Schwartz M; Zwibel H
    Mult Scler Relat Disord; 2015 Jan; 4(1):75-82. PubMed ID: 25787057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.
    Kulakova OG; Tsareva EY; Lvovs D; Favorov AV; Boyko AN; Favorova OO
    Pharmacogenomics; 2014 Apr; 15(5):679-85. PubMed ID: 24798724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.